Gilead Sciences Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $76.28
- Today's High:
- $77.23
- Open Price:
- $76.99
- 52W Low:
- $59.7877
- 52W High:
- $87.6022
- Prev. Close:
- $77.04
- Volume:
- 3728503
Company Statistics
- Market Cap.:
- $95.99 billion
- Book Value:
- 16.967
- Revenue TTM:
- $27.38 billion
- Operating Margin TTM:
- 35.75%
- Gross Profit TTM:
- $21.62 billion
- Profit Margin:
- 20.03%
- Return on Assets TTM:
- 9.77%
- Return on Equity TTM:
- 26.35%
Company Profile
Gilead Sciences Inc had its IPO on 1992-01-22 under the ticker symbol GILD.
The company operates in the Healthcare sector and Drug Manufacturers-General industry. Gilead Sciences Inc has a staff strength of 17,000 employees.
Stock update
Shares of Gilead Sciences Inc opened at $76.99 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $76.28 - $77.23, and closed at $76.8.
This is a -0.31% slip from the previous day's closing price.
A total volume of 3,728,503 shares were traded at the close of the day’s session.
In the last one week, shares of Gilead Sciences Inc have increased by +0.2%.
Gilead Sciences Inc's Key Ratios
Gilead Sciences Inc has a market cap of $95.99 billion, indicating a price to book ratio of 5.3231 and a price to sales ratio of 4.0018.
In the last 12-months Gilead Sciences Inc’s revenue was $27.38 billion with a gross profit of $21.62 billion and an EBITDA of $12.16 billion. The EBITDA ratio measures Gilead Sciences Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Gilead Sciences Inc’s operating margin was 35.75% while its return on assets stood at 9.77% with a return of equity of 26.35%.
In Q2, Gilead Sciences Inc’s quarterly earnings growth was a negative -8.8% while revenue growth was a positive 5.4%.
Gilead Sciences Inc’s PE and PEG Ratio
- Forward PE
- 13.1926
- Trailing PE
- 17.7103
- PEG
- 0.716
Its diluted EPS in the last 12-months stands at $4.35 per share while it has a forward price to earnings multiple of 13.1926 and a PEG multiple of 0.716. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Gilead Sciences Inc’s profitability.
Gilead Sciences Inc stock is trading at a EV to sales ratio of 4.8563 and a EV to EBITDA ratio of 17.3418. Its price to sales ratio in the trailing 12-months stood at 4.0018.
Gilead Sciences Inc stock pays annual dividends of $2.96 per share, indicating a yield of 4.06% and a payout ratio of 45.15%.
Balance sheet and cash flow metrics
- Total Assets
- $62.34 billion
- Total Liabilities
- $13.96 billion
- Operating Cash Flow
- $-483000000.00
- Capital Expenditure
- $139 million
- Dividend Payout Ratio
- 45.15%
Gilead Sciences Inc ended 2024 with $62.34 billion in total assets and $0 in total liabilities. Its intangible assets were valued at $62.34 billion while shareholder equity stood at $21.09 billion.
Gilead Sciences Inc ended 2024 with $2.11 billion in deferred long-term liabilities, $13.96 billion in other current liabilities, 1000000.00 in common stock, $15.14 billion in retained earnings and $8.31 billion in goodwill. Its cash balance stood at $5.70 billion and cash and short-term investments were $8.00 billion. The company’s total short-term debt was $4,037,000,000 while long-term debt stood at $21.21 billion.
Gilead Sciences Inc’s total current assets stands at $15.41 billion while long-term investments were $1.33 billion and short-term investments were $8.00 billion. Its net receivables were $4.23 billion compared to accounts payable of $622.00 million and inventory worth $3.18 billion.
In 2024, Gilead Sciences Inc's operating cash flow was $-483000000.00 while its capital expenditure stood at $139 million.
Comparatively, Gilead Sciences Inc paid $0.45 in dividends in 2024.
Other key metrics
- Current Trading Price
- $76.8
- 52-Week High
- $87.6022
- 52-Week Low
- $59.7877
- Analyst Target Price
- $91.38
Gilead Sciences Inc stock is currently trading at $76.8 per share. It touched a 52-week high of $87.6022 and a 52-week low of $87.6022. Analysts tracking the stock have a 12-month average target price of $91.38.
Its 50-day moving average was $77.23 and 200-day moving average was $80.09 The short ratio stood at 3.31 indicating a short percent outstanding of 0%.
Around 10% of the company’s stock are held by insiders while 8684.5% are held by institutions.
Frequently Asked Questions About Gilead Sciences Inc
Similar Industry Stocks (Drug Manufacturers-General)
Most Active
Top Gainers
Top Losers
About
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Merck & Co, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Merck & Co, Inc. and Tentarix Biotherapeutics Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.